Comparative proteomic profiles of meningioma subtypes

Cancer Research

Volumn 66, Issue 20, 2006, Pages 10199-10204

  Okamoto, Hiroaki ^a,b   Li, Jie ^a   Vortmeyer, Alexander O ^a   Jaffe, Howard ^a   Lee, Youn Soo ^c   Gläsker, Sven ^a   Sohn, Tae Sung ^a   Zeng, Weifen ^d   Ikejiri, Barbara ^a   Proescholdt, Martin A ^e   Mayer, Christina ^e   Weil, Robert J ^a,d   Oldfield, Edward H ^a   Zhuang, Zhengping ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b SAGA UNIVERSITY   (Japan)

^c The Catholic University of Korea   (South Korea)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; MENINGIOMA; MICRODISSECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; TUMOR CLASSIFICATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; WORLD HEALTH ORGANIZATION;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MENINGEAL NEOPLASMS; MENINGIOMA; PROTEOMICS; UP-REGULATION;

EID: 33750535006     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0955     Document Type: Article

References (45)

1. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P, Cavenee WK, editors. Tumours of the nervous system. Lyon: IAPC Press; 2000. p. 176-84.
2. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery 1993;33:955-63.
3. Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 2005;57:538-50; discussion -50.
4. Ng HK, Wong AT. Expression of epithelial and extracellular matrix protein markers in meningiomas. Histopathology 1993;22:113-25.
5. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
6. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1999;1:44-51.
7. Kleihues P, Burger PC, Collins VP, E.W. N, Ohgaki H, Cavenee WK. Glioblastoma. In: Kleihues P, Cavenee WK, editors. Tumours of the nervous system. Lyon: IAPC Press; 2000. p. 29-39.
8. Weber RG, Bostrom J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997;94:14719-24.
9. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 2004;101:210-8.
10. Furuta M, Weil RJ, Vortmeyer AO, et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 2004;23:6806-14.
11. Iwadate Y, Sakaida T, Hiwasa T, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004; 64:2496-501.
12. Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004;70: 183-202.
13. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999;85:2046-56.
14. Koga Y, Naraparaju VR, Yamamoto N. Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-hearing mice. Proc Soc Exp Biol Med 1999;220:20-6.
15. Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst 2002;94:1311-9.
16. Kisker O, Onizuka S, Becker CM, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40.
17. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004;22: 340-5.
18. Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 1997;75:202-7.
19. Horiuchi A, Nikaido T, Taniguchi S, Fujii S. Possible role of calponin hi as a tumor suppressor in human uterine leiomyosarcoma. J Natl Cancer Inst 1999;91: 790-6.
20. Takahashi K, Yamamura H. Studies and perspectives of calponin in smooth muscle regulation and cancer gene therapy. Adv Biophys 2003;37:91-111.
21. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998;76:402-12.
22. Zanetta JP. Structure and functions of lectins in the central and peripheral nervous system. Acta Anal (Basel) 1998;161:180-95.
23. Camby I, Belot N, Lefranc F, et al. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 2002;61:585-96.
24. Rorive S, Belot N, Decuestecker C, et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 2001;33:241-55.
25. Yamaoka K, Mishima K, Nagashima Y, Asai A, Sanai Y, Kirino T. Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J Neurosci Res 2000;59:722-30.
26. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog V. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001;20:7486-93.
27. Park SH, Chung YM, Lee YS, et al. Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin Cancer Res 2000;6:4915-20.
28. Yo YD, Chung YM, Park JK, Ahn CM. Kim SK, Kim HJ. Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death. Exp Mol Med 2002;34:273-7.
29. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 2003;301:513-7.
30. Oh P, Li Y, Yu J, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004;429:629-35.
31. Behne D, Kyriakopoulos A. Mammalian selenium-containing proteins. Annu Rev Nutr 2001;21:453-73.
32. Chen G, Wang H, Miller CT, et al. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 2004;202: 321-9.
33. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11:630-9.
34. Morrison EE, Wardleworth BN, Askham JM, Markham AF, Meredith DM. EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle. Oncogene 1998;17:3471-7.
35. Varga AE, Stourman NV, Zheng Q, et al. Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-β. Oncogene 2005;24: 5043-52.
36. Raval GN, Bharadwaj S, Levine EA, et al. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 2003;22:6194-203.
37. Hughes JA, Cooke-Yarborough CM, Chadwick NC, et al. High-molecular-weight tropomyosins localize to the contractile rings of dividing CNS cells but are absent from malignant pediatric and adult CNS tumors. Glia 2003;42:25-35.
38. Takashima M, Kuramitsu Y, Yokoyama Y, et al. Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 2005;5:1686-92.
39. Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6:180-4.
40. Lomas J, Bello MJ, Arjona D, et al. Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 2005;42: 314-9.
41. Muller P, Henn W, Niedermayer I, et al. Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res 1999;5:3569-77.
42. Wrobel G, Roerig P, Kokocinski F, et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 2005; 114:249-56.
43. Simon M, von Deimling A, Larson JJ, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 1995;55:4696-701.
44. Mihaila D, Jankowski M, Gutierrez JA, et al. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Clin Cancer Res 2003;9:4443-51.
45. Rempel SA, Ge S, Gutierrez JA. SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 1999;5:237-41.